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Surgical Therapy for PD
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INTRODUCTION
Parkinson's Disease (PD) is a progressive neurologic disease caused by loss of dopaminergic neurons in the midbrain substantia nigra. Decreased activation of dopamine
dependent motor pathways results in the classic features of PD including tremor, bradykinesia, rigidity, and gait impairment. The gold standard treatment of Parkinson's Disease
(PD) is levodopa, which acts to replenish deficient endogenous dopamine production,
combined with carbidopa, a decarboxylase inhibitor to decrease peripheral breakdown
of levodopa.
Early in the disease, the combination of carbidopa and levodopa (CD-LD) works remarkably well, with stable symptom control lasting longer than four hours. However, as
the disease progresses, the response to levodopa begins to shorten and mirrors the
half-life of CD-LD (roughly 90 minutes). This leads to extended “off” time without
symptom control, and shorter periods of “on” time.1 Increasing frequency and/or doses
of levodopa may be used to prolong “on” time, but this leads to increased dopaminergic
side effects including dyskinesia. Dyskinesia and other motor complications including
wearing-off occur in up to 90% of patients treated with levodopa for 5-10 years.1 Patients
may ultimately experience rapid cycling between states of dyskinesia and “off” time,
with minimal “on” time. 2

IPX066, known by the trade name RYTARY,
is a carbidopa-levodopa capsule manufactured by Impax Laboratories that is
designed to provide a more sustained, less
variable therapeutic level of levodopa.11
The mechanism of action is identical to
other formulations of CD-LD as described
above, however it is prepared as a multiparticulate capsule with both immediate
and extended release components.12,13 It
was developed to provide a longer duration
of “on” time, less dyskinesia, and less need
for adjunctive medications compared to
standard CD-LD preparations.11

A review of all adjunctive medications and their role in treating the fluctuations associated with PD is outside the scope of this article and we would refer readers to the
American Academy of Neurology Practice Parameters and other reviews for further
detail.6 An ideal therapy would provide a patient with continuous moderate dopaminergic activity, eliminating the symptoms and side effects associated with peaks and
troughs. Continuous levodopa treatments have been shown to be superior to intermittent dosing for dyskinesias with Stocchi noting that an oral continuous method would
be ideal.7

Early trials focused on the safety and
pharmacokinetics of RYTARY. The initial
open-label crossover comparison of
RYTARY versus standard CD-LD formulations focused on safety, side effects, and
pharmacokinetics. 12,14 While limited by
small sample size and open-label format,
the results were very promising regarding
the potential for RYTARY in providing
sustained benefit to patients. Both
RYTARY and immediate release CD-LD
reached 50% peak LD plasma concentrations (Cmax) around 45 minutes; however,
the duration of time spent above Cmax
for RYTARY was 4 hours compared with
1.4 hours for immediate release CD-LD.
When measured clinically, RYTARY
provided a significant decrease in the
Unified Parkinson’s Disease Rating Scale
(UPDRS) score 3-6 hours after a single
dose compared to immediate release
CD-LD, with more than half of patients
still experiencing “on” time at 6 hours.14

Deep brain stimulation (DBS) revolutionized PD treatment, providing thousands of
patients with continuous motor benefits with less dyskinesia, with long-term studies
showing sustained benefits.8 Nevertheless, a number of patients are not eligible for the
procedure due to medical, neuropsychological, or even psychosocial contraindications.
Please refer to the numerous guidelines currently available describing assessment of
surgical candidacy.9,10 Additionally, eligible candidates may simply not be ready or interested in undergoing an invasive brain surgery. Fortunately in January 2015, two novel
therapies (RYTARY and DUOPA) were introduced simultaneously in the United States
that promise to bridge the gap between medical treatment and DBS therapy for PD.

This led to several randomized phase
III trials of RYTARY in different clinical
settings. ADVANCE-PD was a large
(471 patients) multicenter, randomized,
double-blind trial comparing RYTARY to
immediate release CD-LD in PD patients
with motor fluctuations.15 After open label
dose titration to optimum doses of both
RYTARY and immediate release CD-LD,

Strategies to combat this rapid cycling center on extending the half-life and bioavailability of levodopa or using adjunctive medications to prolong dopaminergic activity,
increasing trough levels while reducing peak blood levels that lead to dyskinesia. 2 The
original controlled release carbidopa-levodopa tablets (CR, ER, SA) lack the ability to
provide immediate symptom that is often needed.3 Entacapone co-administration may
prolong “on” time in advanced PD patients,4 but has been associated with an increased
incidence of dyskinesia in early PD patients in the STRIDE-PD trial.5

28

CARBIDOPA/LEVODOPA
EXTENDED RELEASE
CAPSULE

JHN JOURNAL

New Parkinson's Disease Treatment

patients were randomized to one treatment for 13 weeks. RYTARY provided a
decrease in reported “off” time of 1.17
hours, an increase in “on” time without
troublesome dyskinesia of 0.93 hours,
and a decrease in UPDRS scale of 4.04.
The total Levodopa dose for RYTARY was
1630 mg divided over 3.6 doses a day
compared to 814.5 mg over 5 doses for
immediate release CD-LD. Side effect
profiles and frequencies were similar
between the groups. The major limitation
in the study was the large dropout rate
during transition from immediate release
CD-LD to RYTARY, with 13% of patients
unable to transition due to either side
effects or poor efficacy.
APEX-PD was a large (381 patients) multicenter, randomized, double-blind trial
assessing RYTARY as the initial dopaminergic therapy in early levodopa-naïve
PD patients.13 Eligible patients with early
stage PD (Hoehn and Yahr stage I, II, or III)
who had not received any levodopa for 30
days were randomized to different doses
of RYTARY or placebo. UPDRS parts II and
III scores improved dramatically in the
treatment arms versus placebo (between
11.7 and 14.9 for different doses) in addition to significantly improved quality
of life scores. Higher doses of RYTARY
were associated with increased side
effects, however, which again resulted in
increased dropout rates up to 15.3%.
Finally, the ASCEND-PD trial by Stocchi
et al. studied RYTARY in advanced PD
patients who continued to have motor
fluctuations despite stable regimens
of CD-LD with entacapone. 16 In this
moderately sized (110 patients) randomized, double-blind, double dummy
crossover study, patients spent two weeks
receiving either RYTARY or CD-LD plus
entacapone then switched treatments
following a washout period. RYTARY was
associated with a 1.4-hour decrease in
“off” time and a 1.4-hour increase in “on”
time without troublesome dyskinesia.
Subjects on RYTARY averaged 3 doses a
day totaling 1495 mg levodopa compared
with subjects on CD-LD plus entacapone
who averaged 4-to-5 doses a day totaling
600-800 mg. Side effects were more
prevalent in the RYTARY groups, with
20.2 % of patients experiencing any side
effect compared to 13.6% of CD-LD plus
entacapone patients.

In all of these trials, side effect profiles
were similar between RYTARY and
other levodopa formulations. This is not
unexpected, as the major side effects
of nausea, vomiting, diarrhea, dizziness,
falls, dyskinesia, confusion, and insomnia
are likely secondary to dopaminergic
activity. 11,13,14,15,16,17 Slightly increased
side effect frequency in the RYTARY
arms may be due to higher total doses
of levodopa, rapid dose titration, or the
need for post-synaptic adjustments to
the change in pharmacokinetics. Patients
who completed the above trials were
eligible to enroll in a nine-month open
label extension by Waters et al., which
confirmed the overall tolerability and
safety of RYTARY over a longer treatment
duration.18
Despite improved efficacy, similar
side effect profiles, and reduced dose
frequency, a major deterrent to initiating
RYTARY is the transition period from
immediate release CD-LD. The 10-15%
dropout rates seen with RYTARY in the
above trials suggest that the transition to
RYTARY may be difficult for some patients
due to either poor initial efficacy during
titration or side effects. However, the vast
majority of patients were able to make
the switch, with 87.2% successful from
immediate release CD-LD and 82.7% from
CD-LD entacapone formulations.19
Conversion from CD-LD to RYTARY
should be based on a patient’s total daily
dose of immediate release levodopa.
Slightly less than a two-to-one ratio
of levodopa in RYTARY to immediaterelease CD-LD was used in the Hauser et
al. trials,11,14,15 and is the recommended
dosing conversion in the FDA prescribing
information.20 In addition, patients often
need further increases in doses after the
initial switchover. To improve compliance
in particularly sensitive patients, Hauser
suggests changing only the AM dose
from immediate release CD-LD to RYTARY
and titrating that dose to desired effect.21
Once the optimal dose is found, the entire
regimen can be changed to RYTARY
without spending the entire day outside
their therapeutic window. Patients starting
RYTARY as their initial medication should
take 95 mg TID and increase to 145 mg
TID after 3 days if additional levodopa is
needed.21 Like immediate-release CD-LD,
RYTARY absorption is improved on an

empty stomach due to less competition
with protein. Alternatively, taking any
levodopa preparation with food can alleviate GI side effects if they occur.

LEVODOPA-CARBIDOPA
INTESTINAL GEL
Levodopa-carbidopa intestinal gel (LCIG),
is a novel CD-LD enteral suspension
approved for the treatment of motor fluctuations in advanced Parkinson’s disease
(PD). Manufactured by AbbVie, Inc. in the
U.S. as DUOPA, it has been available in
select countries in the European Union
since 2004 as DUODOPA. Powered by
a CADD-1400 Legacy Pump, DUOPA
allows for continuous 16-hour CD-LD
administration into the proximal jejunum
via a gastrostomy or PEG with a jejunal
extension. The medication cassettes must
be refrigerated prior to use and administered at room temperature. Standard daily
dosing is divided into a morning dose,
a daily 16-hour continuous dose, and
additional boluses in case of inadequate
response – each of which are calculated
from the patient’s standard daily dose of
intermediate-release CD-LD and titrated
to suit their needs.22
The efficacy of DUOPA in managing
motor complications has been demonstrated in several studies. Olanow et.
al. completed a 12-week, randomized,
double-blinded, double dummy trial
comparing DUOPA intestinal infusion to
immediate-release CD-LD in 71 patients
with advanced PD and greater than three
hours of reported “off” time per day.23
After undergoing PEG-J placement,
patients were randomized to receive daily
16-hour DUOPA infusion or immediaterelease oral CD-LD capsules with a
matching placebo gel. Patients recorded
their motor status every 30 minutes to
indicate their status as “off,” “on” without
dyskinesia, “on” with troublesome dyskinesia, or sleeping. The LCIG group was
found to have clinically significant reductions in “off” time from baseline and when
compared to the controls (-4.04 hours
from baseline, -1.91 hours compared
to control; P = 0.0015). Patients also
reported statistically significant increases
in “on” time without troublesome dyskinesia (+4.11 hours from baseline, +1.86
hours compared to control; P = 0.0059)
as well as “on” time without dyskinesia
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(+3.37 hours from baseline, + 2.28 hours
compared to control; P = 0.0142). The
average daily dose of DUOPA was 1117
mg/day compared with 1351 mg/day of
immediate-release oral CD-LD, meaning
that the results were not likely to be
attributable to significant increases in
CD-LD dosing.23
The long-term efficacy of DUOPA has also
been observed in longer-term prospective and double-blinded trials. Fernandez
et. al. completed a 54-week, open-label
prospective study of 354 patients on
DUOPA monotherapy, which revealed a
significant decrease in mean daily “off”
time and an increase in “on” time with
and without troublesome dyskinesia. 24 Of
the 272 patients who completed the trial
from Weeks 4-54, “off” time decreased
by 65% (-4.4 ± 2.9 hours per day hours; P
< 0.001), “on” time without troublesome
dyskinesia increased by 62.9% (+4.8
± 3.4 hours; P < 0.001), and “off” time
decreased by 22.5% (-0.4 ± 2.8 hours per
day; (P = 0.023). Slevin, et al. documented
that, compared with immediate-release
CD-LD in a 12-week double-blind,
double-dummy trial, LCIG-naïve patients
showed increased “on” time without
troublesome dyskinesia (+2.19 hours/day;
P < 0.05) and decreased “off” time (-2.27
hours/day; P < 0.05).25 Furthermore,
patients continuing on LCIG presented
with sustained improvements in “off”
time, further increases in “on” time, and
quality-of-life metrics in long-term care.
DUOPA has been approved for use in
43 countries worldwide, which has
provided opportunities for long-term
patient experience studies. 23 Monitoring
a cohort of 59 PD patients on LCIG
therapy for 7 years, Zibetti, et. al. found
statistically significant improvements in
UPDRS-related complications of therapy
among the 41 patients who completed
the study. 26 Other significant findings
included a decrease in the duration (30%;
P = 0.002), disability (48%; P = 0.001), and
pain (78%; P = 0.020) from dyskinesia as
well as a 49% decrease (P = 0.001) in offperiod duration). 54% of patients reported
an improvement in gait disorders, while
only 18% reported improvement in dysarthria. Caceres-Redondo et. al. reported
similar findings in a six-year observation
of 29 LCIG patients, with significant
improvements in UPDRS IV total score,
“off” period duration, and dyskinesia. 27
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The most common adverse reactions
were related to the placement of tubes
for DUOPA administration and included
implant site erosion, ulcer, infection,
intestinal tube dislocation, occlusion/
kinking, PEG internal retention failure,
intestinal complications (ischemia,
hemorrhage, obstruction, perforation,
ileus, peritonitis, pneumoperitoneum,
and bezoar). 22,26 Slevin et. al. reported
an overall decrease in the incidence of
adverse events throughout treatment. 25
Other less-reported complications
include the onset of “sleep attacks”
during daily activities, an increase in the
frequency of orthostatic hypotension
(exacerbated with concurrent administration of antihypertensive drugs), as well
psychiatric manifestations (hallucinations,
psychoses, depression – 11% versus 3%,
and loss of impulse control). The treatment is also associated with an increased
blood urea nitrogen (13% in DUOPA versus
4% in oral intermediate-release LC) as
well as increased creatinine phosphokinase (17% versus 7%) of uncertain clinical
significance. Non-selective MAO inhibitors are contraindicated due to a risk of
hypertension and must be discontinued
two weeks before treatment initiation. 22
An emerging side effect that requires
further study is a sub-acute to chronic
generalized polyneuropathy linked to
DUOPA therapy. 5% of patients (19/412) in
DUOPA clinical trials developed a sensorimotor axonal polyneuropathy. There is
emerging evidence that this phenomenon may be linked to impaired Vitamin
B12 metabolism from long-term CD-LD
therapy and not confined to LCIG. Ceravalo et. al. demonstrated that PD patients
on long-term levodopa therapy were 2.38
times more likely to develop neuropathy
compared to those with short-term
LC therapy and no levodopa exposure,
while having significantly higher doses of
levodopa, higher levels of homocysteine,
and lower levels of vitamin B12. 28 These
observations suggest careful examination, laboratory analysis, and potentially
electromyographic studies prior to the
initiation of any long-term levodopa
therapy.
Pederson et al. established practical
guidelines for instituting LCIG and
evaluating, treating, and supporting
LCIG patients in a Movement Disorders
Clinic. 29 Prior to discontinuation of

their normal PD medications to begin
the DUOPA trial period, staff should be
aware of the anxiety that many patients
will feel after stopping their medication.
Prior to PEG-J placement, the physician
and patient must work together to assess
responsiveness to the therapy, willingness to undergo long-term therapy, and
establish expectations about the efficacy
of the treatment. Before discharge, staff
should work to familiarize patients with
all aspects of the device, stressing that
the pump is pre-programmed with an
individually titrated dose. The device
should be checked biannually for proper
functioning in addition to the patient’s
conference with their physician regarding
the efficacy of the treatment. Patients
should also be educated and provided
with accouterments (i.e. cooling bags)
that will allow them to continue LCIG
therapy while maintaining their lifestyle
and interests. Since the most frequent
complications of the intervention involve
maintenance of the tube itself, it is
recommend that Movement Disorder
centers coordinate with proceduralists (Gastroenterology/Interventional
Radiology) to establish an emergency
response center. 29

CONCLUSION
Overall, RYTARY and intestinal DUOPA
are effective therapies that serve to meet
major unmet needs in the treatment of
PD. There is extensive trial data showing
RYTARY is safe and effective for advanced
PD. Initial data on its use as a first-line
treatment in early PD is promising, though
further studies are needed comparing
RYTARY to immediate release CD-LD in
this patient population.
DUOPA is an effective and reversible alternative to DBS in patients with advanced
PD. DUOPA has been used internationally for some time, and with recent FDA
approval, it is gaining momentum in the
United States. Its primary indication is to
treat advanced PD patients who cannot
control symptoms adequately with
medical therapies available and who
either are not candidates for DBS or who
are unable or unwilling to go through the
rigors of brain surgery. Further study and
clinical experience in the U.S. will hopefully provide further data on its efficacy
and safety profile.
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